



Yourgene
Health

ENABLING
SCIENTIFIC
ADVANCES
to POSITIVELY
IMPACT
HUMAN
HEALTH

Your genes. Your health.



Annual General Meeting

28 September 2021



Disclaimer

THIS INFORMATION IS CONFIDENTIAL AND IT IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE COPIED, REPRODUCED, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. THIS PRESENTATION IS NOT FOR DISTRIBUTION IN THE UNITED STATES, THE REPUBLIC OF SOUTH AFRICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

These presentation slides (the "Slides"), the information communicated during any delivery of the Slides (howsoever delivered), including but not limited to any information communicated in any question and answer session and any document or material distributed at or in connection with the Slides (together the "Information") has been prepared by Yourgene Health plc (the "Company", and such term shall also be deemed to include any subsidiaries of the Company) for the sole use at a presentation (the "Presentation") relating to the annual results of the Company for the year ended 31 March 2019. The Information is provided on a confidential basis and is personal to the recipient. The Information does not contain or constitute or form part of an admission document or prospectus nor does the Information contain, constitute, or form part of any offer or invitation to purchase or subscribe for any securities of the Company, or contain or constitute or form part of any solicitation of any offer to purchase or subscribe for any securities of the Company. The Information should not be relied on in connection or a decision to purchase or subscribe for any securities or act as any inducement to enter into any contract or investment decision in relation thereto. The Information does not constitute a recommendation or advice by the Company, Cairn Financial Advisors ("Cairn") as the company's nominated advisor or their respective shareholders, directors, officers, partners, employees, agents, affiliates, representatives or advisors ("Affiliates") regarding any decision to sell or purchase securities in the Company. Accordingly, the Information is being supplied to you solely for your information only. If you are considering engaging in any investment activity, you should seek appropriate independent advice and make your own assessment. The communication of the Information to you should not be taken as any form of commitment on the part of the Company to proceed with any transaction and the Company reserves its right to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company, Cairn or their respective Affiliates be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. The Information is strictly private and confidential and contains material non-public information. The Information may not, without the consent of Cairn and the Company, be reproduced, disseminated, distributed or otherwise disclosed to any other person or published, in whole or in part, for any purpose. No reliance may be placed, for any purpose whatsoever, on the Information or the completeness or accuracy of the Information. No responsibility is accepted, and to the fullest extent permitted by law or regulation, no representation, warranty or other assurance is made or given, in either case, expressly or impliedly, by or on behalf of the Company, Stifel, or their respective Affiliates or any other person as to the accuracy, completeness, fairness or reasonableness of the Information or any opinions contained therein. Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the Information or in connection with it or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to, or in connection with, the Information. The Information does not purport to contain all of the information that may be required to evaluate the Company and may be in preliminary or draft form. The Information is subject to updating, completion, revision, verification and amendment, and such information may change materially. Neither Cairn nor the Company nor their respective Affiliates are under any obligation to verify, update or keep current the Information. The Information may contain forward-looking statements, which relate, inter alia, to the Company's proposed strategy, plans and objectives. Forward-looking statements are sometimes identified by the use of terminology such as "believes", "expects", "may", "will", "could", "should", "shall", "risk", "intends", "estimates", "aims", "plans", "predicts", "continues", "assumes", "positions" or "anticipates" or the negatives thereof, other variations thereon or comparable terminology. By their very nature, such forward-looking information requires the Company to make assumptions that may or may not materialise. Such forward-looking statements may be price sensitive and involve known and unknown risks, uncertainties and other important factors beyond the control of the Company that could cause the actual performance or achievements of the Company to be materially different from such forward-looking statements. Past performance of the Company cannot be relied upon as a guide to future performance. Accordingly, you should not rely on any forward-looking statements and neither the Company nor Cairn nor their respective Affiliates accept any obligation to disseminate any updates or revisions to such forward-looking statements or any other statements in the Information. No statement in the Information is intended as a profit forecast or a profit estimate and no statement in the Information should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. The Information contains certain financial information which is subject to rounding or approximation. The Information may also contain management estimates. Such estimates have been made in good faith and represent the genuine belief of applicable members of management. Those management members believe that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete, and no representation or warranty (express or implied) is given that such estimates are so founded. The Company, Cairn and their Affiliates do not undertake any obligation to correct or complete any estimate whether as a result of becoming aware of information (new or otherwise), future events or otherwise. The Information may contain certain material information that is confidential, price-sensitive and which has not been publicly disclosed. By your receipt of this Presentation you recognise and accept that some or all of the information in this Presentation may be "inside information" as defined in Article 7 of the Market Abuse Regulation (Regulation 596/2014) ("MAR") and section 56 of the Criminal Justice Act 1993 ("CJA"). You recognise and accept that such information is being provided to you by the Company pursuant to Article 17(8) of MAR and Disclosure Guidance and Transparency Rule 2.5.7G(2) and you confirm, warrant and undertake that you will not: (i) deal in securities that are price-affected securities (as defined in the CJA) in relation to the inside information or encourage another person to deal in price-affected securities or disclose the information except as permitted by the CJA or before the inside information is made public; (ii) deal or attempt to deal in a financial instrument to which MAR applies on the basis of the inside information; (iii) disclose the inside information to another person other than in the proper course of the exercise of your employment, profession or duties; or (iv) engage in behaviour based on any inside information which would breach MAR. The Information is only directed at, persons who are: (a) outside of the United States; (b) in member states of the European Economic Area other than the United Kingdom and who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (as defined below); and (c) in the United Kingdom and are qualified investors and also (i) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities falling within falling within Articles 49(2)(a) to (d) of the Order; or (iii) other persons to whom it can otherwise lawfully be distributed (each a "Relevant Person"). If you have received the Information and you are not a Relevant Person, you must return it (to the extent technologically feasible) to Stifel or the Company immediately. The Information should not be distributed, published, reproduced or otherwise made available in whole or in part by its recipients to any other person or in any other country, locality, state or other jurisdiction where such distribution, publication, availability or use may lead to a breach of any legal or regulatory requirement and, in particular the Slides may not be taken or transmitted or distributed, directly or indirectly, into the United States, or to persons with an address in Australia, the Republic of South Africa, Japan or Canada. It is a condition of you attending the Presentation or receiving the Information that you agree to be bound by the foregoing limitations and restrictions and, in particular, you will be taken to have further represented, warranted and undertaken that: (i) you have read and agree to comply with the contents of this disclaimer; (ii) you are a Relevant Person and you will observe the foregoing provisions, limitations and conditions; (iii) you will keep the Information confidential and take reasonable steps to preserve such confidentiality; and (iv) following the Presentation, you will not at any time have any discussion, correspondence or contact concerning the Information with any of the directors or employees of the Company or its subsidiaries nor with any of their suppliers or customers, or any governmental or regulatory body without the prior written consent of the Company.

AGM Team



Adam Reynolds
*Non-executive
Chairman*




Lyn Rees
CEO



Barry Hextall
*CFO &
Company Secretary*



Agenda



- Welcome & Introductions
- Resolutions (Adam Reynolds, Non-executive Chairman)
- Business update with Lyn Rees (CEO)
- Q&A
- Close

Statement and Resolutions


Adam Reynolds: Non-executive Chairman

AGM statement RNS


Ordinary resolutions

1. **THAT** the Company's Annual Report and Accounts for the year ended 31 March 2021, together with the Directors' Report and Auditors Report thereon, be received and adopted.
2. **THAT** Dr Joanne Mason be elected as a Director
3. **THAT** Adam Reynolds, who retires by rotation, be re-elected as a Director.
4. **THAT** Dr Stephen Little, who retires by rotation, be re-elected as a Director.
5. **THAT** Dr Bill Chang, who retires by rotation, be re-elected as a Director.
6. **THAT** Saffery Champness LLP be reappointed as auditors of the Company (the "**Auditors**") to hold office from the conclusion of the AGM until the conclusion of the next Annual General Meeting of the Company at which accounts are laid before the Company.
7. **THAT** the Directors be and are hereby authorised to determine the Auditors' remuneration.
8. **THAT**, subject to the Articles of Association of the Company, the Directors be and are hereby authorised generally and unconditionally for the purposes of Section 551 of the Companies Act 2006 (the "**Act**") to exercise all powers of the Company to allot shares in the Company or to allot equity securities (within the meaning of Section 560 of the Act) and to grant rights to subscribe for, or to convert any security into, equity securities in the Company up to an aggregate nominal amount of £150,000.

Business update



Business update



- Exceptional pipeline of opportunities in Genomic Technologies, especially in the North American market
- Core business rebounding well across all territories
- Unprecedented business activity levels in Genomic Services, especially UK COVID-19 testing services
- The combination of these growth drivers is likely to deliver first half revenues in excess of £15m (*prior year H1: £8.2m; full year 2020-21: £18.3m*).
- Strategic roadmap for growth firmly established and on track

Our long-term strategy remains to build an international molecular diagnostics business of scale, and we have plans to redeploy COVID-generated funds into our core Genomic Service and Genomic Technology business streams.



Investing in the future

Yourgene Health in Canada



- Investment in a larger facility in Vancouver to enable transformational growth in manufacturing scale up
- Strengthened commercial team with support across North America and expanded Vancouver team with manufacturing and engineers
- Announced US contract wins now in mobilisation stage for H2 commercial launches by the customer
- Active pipeline of blue-chip opportunities
- LightBench™ platform, reagents and consumables available through Yourgene global distribution channel network
- First and second equity earn-out milestones achieved

Investing in the future

APAC




New lab facility U-Town in Taipei

- New improved high spec laboratory facility in Taipei is now operational
- Historic private clinical research customer sample volumes have restarted with a new programme for oncology screening focused on myeloid testing
- First IONA[®] Nx customer has been installed in Singapore
- IONA[®] Nx approved for sale in Australia with TGA registration
- Re-structured and re-energised routes to market:
 - Growth of commercial team with key personnel appointments
 - New distribution channels established in Taiwan for LightBench[™]

COVID-19

Business update



- COVID-19 testing service operating at capacity of 100,000 tests per month
- DHSC surge testing contract win (non-travel) commenced mid-September 2021 (the first under the Microbiology framework)
 - Laboratory capacity doubled to facilitate
 - Contract runs through November 2021
- UK National Microbiology Framework offers further tender opportunities
- Private PCR testing:
 - Despite the proposed change of UK government regulations for PCR testing we expect to see consistent volumes through to end of October
 - Testing mix will change from November as UK changes take effect, with non-travel continuing and uncertain travel dynamic as number of travellers increase but PCR coverage reduces
- Clarigene® product sales to other COVID testing partners during H1 is approx. £1million
- Invested platform will provide future revenue opportunities outside of COVID

Yourgene Genomic Services

Growth milestones over the last 12 months



- Genomic Services brings together UK and Taiwan laboratories to broadening the clinical and research services offering
- Launched IONA[®] *Care* from the NIPT laboratory offering
 - Extended clinical menu and bringing new clinical customers, including key partners
 - >6,000 NIPT tests processed in UK lab in last 12 months, 20% increase on previous year
- Launched genoSCORE[™]-lab a polygenic risk score for Alzheimers test
- Strengthening pharma partnerships with CRO core services for genotyping, microarray and DNA extraction projects
- Investments in services reaping rewards:
 - Global headcount: 90
 - Expanded and re-fitted laboratories in Manchester and Taipei
 - ISO: 15189 accreditation achieved for COVID testing
- Opportunities to expand into other territories

Outlook


Strong momentum for transformational growth



- FY21 was a year of investment and adaptation
- H1 showing positive rewards from this with strong revenues and recovery
- Core business performing well across the portfolio:
 - Ranger™ Technology / LightBench exciting pipeline and new markets opened up with commercial channels
 - NIPT workflow opportunities progressing in new territories (US, Singapore)
 - CRO core services building on existing partnerships and strong pipeline
- Investments in facilities, quality systems and talent in APAC, Canada and UK are supporting transformational scale-up to supporting compelling growth opportunities
- DHSC contract for surge COVID testing is now live

Our long-term strategy remains to build an international molecular diagnostics business of scale, and we have plans to redeploy COVID-generated funds into our core Genomic Service and Genomic Technology business streams.

Questions & Answers





Close

- Thank you for joining us for the first hybrid /virtual Yourgene Health plc AGM
- Thanks to all our presenters and to “Investor Meet Company” for hosting the event on their platform
- Any questions that we didn’t have time to answer we will try to answer via the IMC portal within the confines of information already disclosed to the market through regulatory notifications
- A copy of this presentation and the recording will also be made available on the IMC portal and the Yourgene Health website

<https://www.investormeetcompany.com/yourgene-health-plc/>

To be kept up to date with Yourgene Health plc news and to receive relevant investor communications on the Company going forward, please email Walbrook PR at yourgene@walbrookpr.com to subscribe



Yourgene Health

www.yourgene-health.com

Yourgene Health Plc
Citylabs 1.0
Nelson Street
Manchester
M13 9NQ
United Kingdom

Telephone: +44 (0)161 669 8122
Email: investors@yourgene-health.com

Lyn Rees
Chief Executive Officer
lyn.rees@yourgene-health.com

Barry Hextall
Chief Financial Officer
barry.hextall@yourgene-health.com